I'll say no more about PCYC after this but some need to see potential as their vision seems to stop at the end
not much futher than the end of their noses. Ibrutinib is the drug PCYC is hanging their hat on and it looks to be a darn good one...but it's ONE drug. CYTK has two GAME CHANGERS that are pretty far along with, of course, OM being the furthest along. PCYC has about half the shares of CYTK outstanding but at the approximate same point in time as CYTK...didn't have the milestone targets that are as enormous in potential payouts as what CYTK does. PCYC has projections by a few respected analysts of being well over $100. EVEN half that gives CYTK $50....what's CYTK's potential?? Of course there's other bio-techs one can pick out and compare with CYTK but it seems to me PCYC's apparently successful drug compares well with CYTK.....time will tell...it always does.
Let's be realistic, my one year target for CYTK is $10 base on positive data from OM PII and ALS PII trials. That is $1.5 B market cap if CYTK reach $10. I believe if OM & ALS PII trials are all successful, then CYTK worth that value. After that, either AMGN buyout or other good news will push it a lot higher.